Your session is about to expire
← Back to Search
Low-Dose tPA in PCI for Heart Attack (STRIVE Trial)
Phase 3
Recruiting
Led By Shamir Mehta, MD
Research Sponsored by Population Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Large thrombus burden with angiographic TIMI Thrombus Grade ≥3 after guidewire crossing
Patients with STEMI undergoing primary PCI
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights
STRIVE Trial Summary
This trial will test whether using a low dose of the drug tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarction (STEMI) can reduce the incidence of post-procedural myocardial blush (MBG) grade 0/1 or distal embolization.
Who is the study for?
This trial is for patients with a severe type of heart attack (STEMI) who can receive treatment within 6 to 12 hours of symptom onset. They must have significant ECG changes and a large clot in the heart's arteries. People at high risk of bleeding, those who've had recent fibrinolytic therapy, or have certain ECG abnormalities cannot join.Check my eligibility
What is being tested?
The STRIVE study tests if adding low-dose tissue plasminogen activator (tPA) during an artery-opening procedure (PCI) can improve blood flow in the heart muscle after STEMI compared to using saline as a control.See study design
What are the potential side effects?
Potential side effects include bleeding complications due to tPA, which helps dissolve clots but may increase bleeding risk elsewhere in the body. Other risks are related to standard PCI procedures.
STRIVE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My heart condition involves a significant blood clot after a procedure.
Select...
I am receiving a procedure to open blocked arteries after a severe heart attack.
STRIVE Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Post-procedural MBG 0/1 or Distal Embolization.
Secondary outcome measures
CV Death, MI, Cardiogenic Shock or New Onset HF
Complete ST-segment resolution.
STRIVE Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Intracoronary tPA 20 mgExperimental Treatment1 Intervention
Group II: Intracoronary tPA 10 mgExperimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
saline
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
tissue plasminogen activator
2003
Completed Phase 1
~130
Find a Location
Who is running the clinical trial?
Heart and Stroke Foundation of CanadaOTHER
124 Previous Clinical Trials
72,130 Total Patients Enrolled
Population Health Research InstituteLead Sponsor
156 Previous Clinical Trials
680,932 Total Patients Enrolled
Shamir Mehta, MDPrincipal InvestigatorMcMaster University, Hamilton Health Sciences, Population Health Research Institute
1 Previous Clinical Trials
5,100 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a specific heart condition called left bundle branch block which would make it difficult to measure a specific outcome of the study.I was in a state of heart failure when I first sought medical help.My heart condition involves a significant blood clot after a procedure.I have not had any recent internal or brain bleeding.I am receiving a procedure to open blocked arteries after a severe heart attack.Your ECG shows specific changes that indicate a serious heart condition called STEMI.I have received a clot-dissolving medication within the last 24 hours.I have no conditions that prevent me from receiving clot-dissolving treatments.I will be treated with a specific heart medication soon.
Research Study Groups:
This trial has the following groups:- Group 1: Intracoronary tPA 10 mg
- Group 2: Intracoronary tPA 20 mg
- Group 3: Placebo
Awards:
This trial has 1 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger